AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

Remember when lip fillers and Botox seemed taboo? In the early 2000s, celebrities especially seemed to be more guarded about ...

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, expectations were $2.98. Operator: Good morning and thank you for standing by.

And that's what we're doing with our customers now in helping them position Botox and Juvederm in our product line for these new patients that are entering their practice. Yes, it's a very good ...

Women.com spoke with Dr. Dennis Schimpf, a Board Certified Charleston, South Carolina Plastic Surgeon who gave us several ...

The National Medical Commission (NMC) has started its probe against 30 doctors who allegedly took pharma freebies in the form of travel and hospitality expenses from AbbVie ...

The latest trend is quiet, demure, and undetectable.

Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include ...

Bhad Bhabie detailed her recent cosmetic procedure, sharing she got a nose job two months after opening up about her health.

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...